Prosecution Insights
Last updated: April 19, 2026
Application No. 18/647,613

Tinted Deodorant Composition

Non-Final OA §103
Filed
Apr 26, 2024
Examiner
COHEN, MICHAEL P
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
C'Est Tout Studio
OA Round
1 (Non-Final)
58%
Grant Probability
Moderate
1-2
OA Rounds
2y 11m
To Grant
86%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allow Rate
484 granted / 829 resolved
-1.6% vs TC avg
Strong +28% interview lift
Without
With
+27.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
48 currently pending
Career history
877
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
55.3%
+15.3% vs TC avg
§102
7.3%
-32.7% vs TC avg
§112
7.7%
-32.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 829 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Status Claims 1-20 are pending and are examined on the merits in this prosecution. CLAIM REJECTIONS Obviousness Rejection The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 1) Claims 1-10 are rejected under 35 U.S.C. 103 as being unpatentable over Scavone (US 2006/0263313 A1), in view of Guyot-Ferreol (“How to Create and Adjust Various Shades of Foundation Adapted to Skin Tones,” downloaded 2-21-2026 from https://sensient-beauty.com/insights/how-to-create-and-adjust-various-shades-of-foundation-adapted-to-skin-tones/; available on the internet 3/15/2019). Scavone teaches antiperspirant compositions comprising: (a) from about 0.1% to about 30% by weight of the composition, of a high-efficacy antiperspirant active; (b) from about 0.05% to about 15% by weight of the composition, of a malodor reducing agent; (c) from about 0.1% to about 35% by weight of the composition, of a thickening agent; (d) from about 10% to about 99% by weight of the composition, of an anhydrous liquid carrier; (e) from about 5 ppm to about 20% by weight of the composition, of a primary fragrance; and (f) from at least about 5 ppm by weight of the composition, of a secondary fragrance that is distinct from the primary fragrance (Abstract). Scavone teaches the composition also contains dyes and/or colorants (pg 8, [0090]). Scavone teaches that the product should provide little or no visible residue after application to the skin (pg 1, [0010]). Scavone does not teach the coloring element as a “tint mixture that mimics a skin tone. Guyot-Ferreol teaches the missing element of Scavone. Guyot-Ferreol teaches a cosmetic tinting mixture for matching a variety of skin tones (Title). Guyot-Ferreol teaches “In general, foundation colors are developed using mineral oxides: titanium dioxide for white, and iron oxides for yellow, red and black. Various combinations of the four basic colors make it possible to create an infinite number of shades.” See pg 4. It is noted that Guyot-Ferreol does not specifically teach a deodorant composition, but one of ordinary skill would recognize that the skin tone composition taught by Guyot-Ferreol are readily applicable to any cosmetic, including a deodorant. For claim 2, Guyot-Ferreol teaches a cosmetic tinting mixture for matching a variety of skin tones from white Caucasian to African American (pg 2), and Scavone teaches that the cosmetic product should provide little or no visible residue after application to the skin; in order for a composition to contain colorants and leave no visible residue after skin application, the color must be homogeneously distributed in the base. For claims 3-8, Guyot-Ferreol teaches a cosmetic tinting mixture comprising “mineral oxides: titanium dioxide for white, and iron oxides for yellow, red and black. Various combinations of the four basic colors make it possible to create an infinite number of shades.” See pg 4. For claim 9, the person of ordinary skill would have had a reasonable expectation of success in selecting a tint mixture comprising a red colorant (6-38%), a yellow colorant (13-31%), and a black colorant (5-56%) of the tint mixture since Guyot-Ferreol teaches a cosmetic tinting mixture comprising “mineral oxides: titanium dioxide for white, and iron oxides for yellow, red and black. Various combinations of the four basic colors make it possible to create an infinite number of shades.” The person of ordinary skill in the art would have found it obvious to optimize within the color ranges taught by Guyot-Ferreol because Guyot-Ferreol teaches that an infinite number of shades can be obtained using only titanium dioxide and iron oxides for yellow, red and black. For claim 10, as discussed above, Scavone teaches a base composition that comprises from about 0.1% to about 35% by weight of the composition of a thickening agent and from about 10% to about 99% by weight of the composition, of an anhydrous liquid carrier (Abstract), overlapping the claimed range of the base element. 2) Claims 11-20 are rejected under 35 U.S.C. 103 as being unpatentable over Scavone (cited above), in view of Guyot-Ferreol (cited above) and Parker (US 2022/0175656 A1). The teachings of Scavone and Guyot-Ferreol are discussed above. The combination of Scavone and Guyot-Ferreol does not teach the amount of ting mixture that mimics a skin tone recited in claim 11. Parker teaches the missing element of the combination of Scavone and Guyot-Ferreol. Parker teaches a deodorizing composition configured to match the user's skin tone. The deodorizing composition is pigmented to match different skin colors ranging from tan to dark brown to avoid leaving a white residue visible on darker skin or clothing (Abstract). Parker teaches the colorant is “present in an amount between 0.9 to 3.7 % by volume of the total deodorant composition” (pg 4, claim 20), an amount within the claimed range. Because the claimed range overlaps with the range disclosed by the prior art, a prima facie case of obviousness exists. For claim 12, Scavone teaches “Antiperspirant compositions of the present invention may further comprise a primary fragrance to help cover or mask malodors resulting from perspiration (pg 6, [0064]). For claims 13-18, as discussed above, cosmetic tinting mixture comprising “mineral oxides: titanium dioxide for white, and iron oxides for yellow, red and black in order to mimic a broad range of skin tones. For claim 19, the person of ordinary skill would have had a reasonable expectation of success in selecting a tint mixture comprising a red colorant (6-38%), a yellow colorant (13-31%), and a black colorant (5-56%) of the tint mixture since Guyot-Ferreol teaches a cosmetic tinting mixture comprising “mineral oxides: titanium dioxide for white, and iron oxides for yellow, red and black. Various combinations of the four basic colors make it possible to create an infinite number of shades.” The person of ordinary skill in the art would have found it obvious to optimize within the color ranges taught by Guyot-Ferreol because Guyot-Ferreol teaches that an infinite number of shades can be obtained using only titanium dioxide and iron oxides for yellow, red and black. For claim 20, Scavone teaches the deodorant is in the form of roll-ons and solid sticks (pg 8, [0091]). The skilled artisan would have expected success in utilizing the amount of tint mixture taught by Parker in the deodorant composition taught by the combination of Scavone and Guyot-Ferreol because the claimed composition requires an amount of tint mixture of 0.05% to 10% and Parker teaches a deodorant composition to match the skin tone of the wearer comprising an amount of tint mixture within the claimed range. CONCLUSION Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL P COHEN whose telephone number is (571)270-7402. The examiner can normally be reached on M-Th 8:30-5:30; F 9-4. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana S. Kaup, can be reached on (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL P COHEN/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Apr 26, 2024
Application Filed
Feb 21, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600990
mRNA INDUCED EXPRESSION OF BONE MORPHOGENIC PROTEIN AND RECEPTOR AND METHODS RELATED THERETO
2y 5m to grant Granted Apr 14, 2026
Patent 12582608
COATINGS FOR GASTRIC RESIDENCE DOSAGE FORMS
2y 5m to grant Granted Mar 24, 2026
Patent 12582581
LAMINATE SHEET FOR COSMETIC, AND COSMETIC SET
2y 5m to grant Granted Mar 24, 2026
Patent 12582669
COMPOSITION CONTROLLING PHARMACOKINETICS IN THE BODY
2y 5m to grant Granted Mar 24, 2026
Patent 12576037
POLYMER-ENCAPSULATED DRUG PARTICLES
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
58%
Grant Probability
86%
With Interview (+27.6%)
2y 11m
Median Time to Grant
Low
PTA Risk
Based on 829 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month